Erschienen in:
01.07.2010 | Therapy in Practice
Lafora disease
Epidemiology, pathophysiology and management
verfasst von:
Thomas S. Monaghan, Dr Norman Delanty
Erschienen in:
CNS Drugs
|
Ausgabe 7/2010
Einloggen, um Zugang zu erhalten
Abstract
Lafora disease is a rare, fatal, autosomal recessive, progressive myoclonic epilepsy. It may also be considered as a disorder of carbohydrate metabolism because of the formation of polyglucosan inclusion bodies in neural and other tissues due to abnormalities of the proteins laforin or malin. The condition is characterized by epilepsy, myoclonus and dementia. Diagnostic findings on MRI and neurophysiological testing are not definitive and biopsy or genetic studies may be required. Therapy in Lafora disease is currently limited to symptomatic management of the epilepsy, myoclonus and intercurrent complications. With a greater understanding of the pathophysiological processes involved, there is justified hope for future therapies.